🇮🇳 India Stock Screener ← Switch market ★ Elite Club ⚡ HerAI

Fredun Pharmaceuticals Limited FREDUN NSE

Company Profile ↓
₹1,470.70
+2.37% 1Y
Mkt Cap₹2,414.61 Cr
P/B8.36
52W High₹1,505.80
52W Low₹1,428.00
Book Value₹171.53

Company Overview

Fredun Pharmaceuticals Limited (FREDUN) is a publicly traded company listed on NSE with a market capitalization of ₹2,414.61 Cr. The valuation, growth and price-trend signals below summarize what matters most to investors and traders evaluating the stock.

Why Investors Should Care

Healthy Capital Returns

Return on capital employed stands at 27.3%.

Consistent Profit Growth

Net profit has compounded at 44.5% per year over the last five years.

Steady Revenue Expansion

Revenue has grown at a 32.2% CAGR over the past five years.

Recent Developments

  • Mar 2026 Revenue of ₹633.33 Cr (+40.2% YoY); net profit ₹32.62 Cr.
  • Trailing 12 Months Year-on-year growth — revenue +40.2%, earnings +65.3%.
  • 5-Year Trend Long-term compounding — revenue CAGR 32.2%, profit CAGR 44.5%.

Growth & Price Performance

Compounded Sales Growth

5 Years:32.16%
1 Year:40.21%

Compounded Profit Growth

5 Years:44.52%
1 Year:65.26%

Stock Price Performance

1 Year:+2.37%
6 Months:-
3 Months:-
1 Month:-

Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.

Technical Snapshot
52-Week Range 55% of range
₹1,428.00 ₹1,505.80
Price Performance
1Y+2.37%

Auto-generated from price history and fundamentals; not investment advice.

⚙Ad space

Price Chart

NSE TradingView

Fundamental Growth Charts

Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.

PROS

  • Healthy ROCE of 27.3%.
  • Compounding revenue at 32.2% over 5 years.
  • Profit CAGR of 44.5% over 5 years.

CONS

No notable concerns flagged.

* The pros and cons are auto-generated from financial metrics.

⚙Ad space

Valuation

Stock P/E
-
Industry PE
-
Forward P/E
-
PEG Ratio
-
Book Value
₹171.53
Price to Book
8.36
P/S
3.72
EV/EBITDA
27.31
Dividend Yield
0.00%

Growth (CAGR)

Revenue 5Y
32.16%
Profit 5Y
44.52%
Revenue (YoY)
40.21%
Earnings (YoY)
65.26%

Profitability & Returns

ROCE
27.29%
ROE
11.58%
ROA
5.08%
Profit Margin
5.15%
Op Margin
14.88%
Gross Margin
26.62%
EPS (Latest Qtr)
₹-
EPS (TTM)
₹0.00

Balance Sheet & Liquidity

Debt/Equity
0.86
Quick Ratio
0.77
Current Ratio
1.68
Debt
₹242.27 Cr
Total Assets
₹642.08 Cr
Current Assets
₹498.17 Cr
Working Capital
₹201.31 Cr

Ownership

Promoter Holding
55.06%
Chg in Prom Hold
-
FII / Inst Holding
0.00%
Chg in FII Hold
-

Financial Snapshot

Enterprise Value
₹2,414.61 Cr
Total Revenue (TTM)
₹633.33 Cr
EBITDA
₹92.73 Cr
Free Cash Flow
₹-61.69 Cr
Operating Cash Flow
₹11.90 Cr
Shares Outstanding
₹1.64 Cr
Gross Margin
26.62%
Payout Ratio
-
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios

Quarterly Results

Figures in INR.

Metric Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026
Revenue 119.40 Cr143.59 Cr159.93 Cr210.41 Cr227.76 Cr
Cost of Revenue 87.30 Cr107.33 Cr114.00 Cr156.10 Cr176.19 Cr
Gross Profit 32.10 Cr36.25 Cr45.92 Cr54.31 Cr51.57 Cr
Operating Expenses 16.53 Cr15.82 Cr21.37 Cr28.58 Cr22.40 Cr
Operating Income 15.57 Cr20.44 Cr24.55 Cr25.73 Cr29.17 Cr
EBITDA 16.99 Cr22.33 Cr26.34 Cr28.88 Cr32.74 Cr
Interest Expense 6.53 Cr7.73 Cr10.55 Cr14.49 Cr8.62 Cr
Pretax Income 9.04 Cr12.71 Cr14.00 Cr11.25 Cr20.55 Cr
Tax Provision 2.27 Cr3.27 Cr3.52 Cr46.81 L7.42 Cr
Net Income 6.77 Cr9.43 Cr10.48 Cr10.78 Cr13.13 Cr
Diluted EPS -----

Profit & Loss (Annual)

Figures in INR.

Metric Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Revenue -274.34 Cr346.58 Cr451.71 Cr633.33 Cr
Cost of Revenue -217.43 Cr273.60 Cr345.49 Cr464.74 Cr
Gross Profit -56.91 Cr72.98 Cr106.21 Cr168.59 Cr
Operating Expenses -31.91 Cr38.78 Cr49.58 Cr74.37 Cr
Operating Income -24.99 Cr34.20 Cr56.63 Cr94.22 Cr
EBITDA -27.88 Cr37.77 Cr52.96 Cr92.73 Cr
Interest Expense -7.56 Cr12.52 Cr20.42 Cr37.49 Cr
Pretax Income -17.51 Cr21.45 Cr27.49 Cr47.00 Cr
Tax Provision -6.70 Cr5.83 Cr7.75 Cr14.38 Cr
Net Income -10.81 Cr15.62 Cr19.74 Cr32.62 Cr
Diluted EPS -7.6411.110.000.00

Balance Sheet (Annual)

Figures in INR.

Metric Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Total Assets -257.28 Cr307.60 Cr487.41 Cr642.08 Cr
Current Assets -216.21 Cr257.20 Cr427.20 Cr498.17 Cr
Cash & Equivalents -2.95 Cr1.07 Cr63.69 L64.93 Cr
Inventory -150.12 Cr175.00 Cr239.89 Cr269.80 Cr
Receivables -34.56 Cr64.85 Cr177.12 Cr92.69 Cr
Total Liabilities -160.90 Cr186.13 Cr346.03 Cr360.46 Cr
Current Liabilities -139.66 Cr166.83 Cr328.10 Cr296.86 Cr
Long Term Debt -15.44 Cr12.80 Cr9.61 Cr56.31 Cr
Total Debt -86.55 Cr105.51 Cr168.38 Cr242.27 Cr
Total Equity -96.38 Cr121.47 Cr141.38 Cr281.62 Cr
Shares Outstanding -1.36 Cr1.41 Cr1.42 Cr1.64 Cr

Cash Flows (Annual)

Figures in INR.

Metric Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Operating Cash Flow --14.41 Cr-43.87 L-16.60 Cr11.90 Cr
Investing Cash Flow --9.40 Cr-7.64 Cr-6.35 Cr-73.59 Cr
Financing Cash Flow -25.18 Cr5.99 Cr26.65 Cr121.45 Cr
Capital Expenditure --9.49 Cr-7.64 Cr-6.11 Cr-73.59 Cr
Free Cash Flow --23.90 Cr-8.08 Cr-22.70 Cr-61.69 Cr
Net Change in Cash -1.36 Cr-2.08 Cr3.70 Cr59.76 Cr

Ratios (Annual)

Figures in %.

Metric Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Gross Margin % -20.7%21.1%23.5%26.6%
Operating Margin % -9.1%9.9%12.5%14.9%
Net Margin % -3.9%4.5%4.4%5.2%
ROE % -11.2%12.9%14.0%11.6%
ROCE % -21.2%24.3%35.5%27.3%

Shareholding Pattern

Insiders
55.06%
Institutions
0.00%
Public Float
0.00%

Analyst View

Loading analyst coverage…

Latest News

Recent headlines for FREDUN

Google News Sun, 06 Sep 2026

Fredun Pharmaceuticals net profit surges 95% in Q1FY27 on revenue jump - scanx.trade

<a href="https://news.google.com/rss/articles/CBMiwgFBVV95cUxOUU1tRUZrRXB5eHExM1B4anRrZWRzV1lWYXlrbWRQQzJlVmN3dWFpTUYyMlVob0kwcFdlTFg2OE1DNFVSVlFSUzQxaGhudUZ1R05TN1VzVmlIbExNaHVrSWVOV3J6ZTZKU0tUTV9rQUpVTkJuaXBmWjBmbTd5UTRBS2hnb0lFbnBFSUdmaF…

Google News hu, 13 Aug 2026

Earnings call transcript: Fredun Pharmaceuticals jumps 10% after Q1 2026 surge - Investing.com

<a href="https://news.google.com/rss/articles/CBMizAFBVV95cUxQYS1Oc0JDTjd4MUpxLS1hRHItNUJTZ3llNzl0X2JPc2ZWUGZycjluRHlmQjJKM1pXT3p1dWM0bk5Fa05Jc3ZEMXYzc0NWRTFIVGdsWXJPMm5Xd19OSEJGYzlkM3dldWFJdUxRSXVEUmVQalo0RHRCbHpoRHBqX1pSa1h5cXN1UGo4akJQTm…

Google News Mon, 17 Aug 2026

Technical Analysis of Fredun Pharmaceuticals Ltd. (NSE:FREDUN) - TradingView

<a href="https://news.google.com/rss/articles/CBMiakFVX3lxTFAwYTNOMHF1OHFLdUd1Ylp2dE9ySjFWal82YnBWRVR0eVNiRFJvMFJHR19jaTFMTllBQkwyVW8xQnF1cTRHdi1LZEdFNDZVaGg5R29ucFY3UDZ2Wmw1M05DZWQtcE03TXBwcXc?oc=5" target="_blank">Technical Analysis of Fr…

Google News Wed, 15 Jul 2026

Bonus issue alert! Last day to buy this microcap pharma stock that rallied 200% in one year - The Economic Times

<a href="https://news.google.com/rss/articles/CBMi9gFBVV95cUxNZmJPbENMV1oydlFjSFJ0Q01GMlUtTG5OcTl6WUZuUF93S1VlUkgzZy0zNUhaWEU4WmNwdl9JeENWenNxVUlSZkhrYVVlSHNlU0czNmZjN1hyX0Z6SXJBQzhLTHFKWHlYN0FRV1R3X0lJdkN1UXNMbTNOeDFGNmhnRVBvMDNROF9xR1ZzNk…

Google News Sun, 30 Aug 2026

Fredun Pharmaceuticals Ltd. Shareholding Pattern – Promoters, FIIs & DIIs - Value Research

<a href="https://news.google.com/rss/articles/CBMikwFBVV95cUxQU0JaalFKUVVsYy1CV0dfUTByc2V0NmVhNGNsZFNhZ2k0UW9NVE1hT0JmQ1U2Tm5nWDlIOENjUEJmVHY2UzJoQ0FYaXgteTd0ZTNfdklZS2tUa1N3RE44UE1HdGxqclViUjhLdWhSQ1NYNE9JdDg4SjJFSng4QVB0MjVHMWlGWlVKei1PT1…

Google News Mon, 25 May 2026

Fredun Pharmaceuticals Q4 profit rises 56%, announces bonus shares - BusinessLine

<a href="https://news.google.com/rss/articles/CBMivAFBVV95cUxQQTNoTC1lZ0NrdXp3aU9MOFVGWGM2NDBiZUlKNnRUWkk1MWplU3FRTUZyU21RcXRteFJBeFUxcWtvN3pzVjg3Sjd5Tks4UTloZ3l5RGVORWF5UjE1bmx1aU5qVjR2aHpHbUlMU052NGFCVFZBdTRnSkRXbFFRR0xmM1JMUkNpOGRIc1BlOU…

FREDUN — Frequently Asked Questions

What is the current share price of Fredun Pharmaceuticals Limited (FREDUN)?

As of 2026-09-08 04:53 IST, Fredun Pharmaceuticals Limited (FREDUN) trades at ₹1,470.70 on NSE. Its 52-week range is ₹1,428.00 to ₹1,505.80.

What is the market capitalisation of FREDUN?

Fredun Pharmaceuticals Limited (FREDUN) has a market capitalisation of ₹2,414.61 Cr on NSE.

What is the return on equity (ROE) of FREDUN?

FREDUN has a return on equity (ROE) of 11.58%. Its return on capital employed (ROCE) is 27.29%.

Is FREDUN a good stock to buy?

This page provides a data-driven analysis of Fredun Pharmaceuticals Limited (FREDUN), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.

Explore More

🔍 All Stock Screens 📈 Technical Screens 💰 Fundamental Screens 🔄 Swing Trading Setups 📐 Chart Patterns 📅 Earnings Calendar 📋 All India Stocks
⚙Ad space